{
    "id": 22966,
    "fullName": "IGF2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "IGF2 over exp indicates an over expression of the Igf2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3481,
        "geneSymbol": "IGF2",
        "terms": [
            "IGF2",
            "C11orf43",
            "GRDF",
            "IGF-II",
            "PP9974"
        ]
    },
    "variant": "over exp",
    "createDate": "05/25/2016",
    "updateDate": "07/14/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6514,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI 885578 inhibited proliferation of colon carcinoma cell lines harboring IGF2 over expression and KRAS G12A in culture, and reduced tumor growth in xenograft models (PMID: 26438154).",
            "molecularProfile": {
                "id": 23605,
                "profileName": "IGF2 over exp KRAS G12A"
            },
            "therapy": {
                "id": 4132,
                "therapyName": "BI 885578",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5673,
                    "pubMedId": 26438154,
                    "title": "BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16211,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Ofev (nintedanib) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7923,
                "therapyName": "BI 885578 + Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16210,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Camptosar (irinotecan) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7925,
                "therapyName": "BI 885578 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 885578 and Adrucil (fluorouracil) resulted in increased tumor growth inhibition compared to the highest single agent in colorectal cancer cell line xenograft models with high IGF2 expression (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 7924,
                "therapyName": "BI 885578 + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16208,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high IGF2 expression was associated with sensitivity to BI 885578 in colorectal cancer (CRC) cell lines in culture, and BI 885578 treatment resulted in decreased IGF1R phosphorylation and AKT phosphorylation in high IGF2-expressing CRC cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 28729397).",
            "molecularProfile": {
                "id": 26235,
                "profileName": "IGF2 over exp"
            },
            "therapy": {
                "id": 4132,
                "therapyName": "BI 885578",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14330,
                    "pubMedId": 28729397,
                    "title": "The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23605,
            "profileName": "IGF2 over exp KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26235,
            "profileName": "IGF2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}